Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

HomeESGO/ESTRO/ESP Endometrial Risk (2021)
Pin your most used calculators here by clicking the star in the dropdown.

ESGO/ESTRO/ESP Endometrial Risk (2021)

Clinical Context & Background

The ESGO-ESTRO-ESP 2021 guidelines incorporate molecular classification (POLE, MMRd, p53) for risk stratification. This calculator approximates the consensus for patients where molecular classification is unknown/unavailable, relying on Stage, Grade, Histology, and LVSI. Note: "Substantial" LVSI significantly increases risk.
Primary Source EvidenceConcin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
Formula Logic
Classification based on Stage, Grade, Histology, and LVSI (Substantial vs Focal).

Reference Data

Risk Group (Molecular Unk)Typical Management
LowObservation
IntermediateBrachytherapy alone
High-IntermediateEBRT +/- Brachytherapy
HighEBRT + Chemotherapy

Share This Calculator

Share:

Related Tools

FIGO GTN Risk ScoreRMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Evidence-based oncology decision support. Verify with clinical guidelines.